

STIC-Biotech/ChemLib

183112

mg

From: Vivlmore, Tracy
Sent: Friday, March 24, 2006 10:13 AM
To: STIC-Biotech/ChemLib
Subject: Sequence search request, application 10/619253

Hello,

For application 10/619,253 please perform a score over length search of nucleotides 2989-3054 of SEQ ID NO: 3. The length is 15-25 and the cutoff is 90%.

Thank you,

Tracy Vivlmore PhD
Remsen 2B-02, AU 1635
Mailbox: 2C-18
Tel: 571-272-2914

STIC-Biotech/ChemLib
10/619,253
2989-3054
15-25
90%

Searcher: Jan
Searcher Phone: 22504
Date Searcher Picked up: 3/27/06
Date completed: 3/27/06
Searcher Prep Time: 60
Online Time: 60

Type of Search
NA# ✓ AA#:
S/L: ✓ Oligomer:
Encode/Transl:
Structure #: Text:
Inventor: Litigation:

Vendors and cost where applicable
STN:
DIALOG:
QUESTEL/ORBIT:
LEXIS/NEXIS:
SEQUENCE SYSTEM: ✓
WWW/Internet:
Other (Specify):

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 27, 2006, 08:31:13 ; Search time 0.001 Seconds
(without alignments)
45.936 Million cell updates/sec

Title: US-10-619-253-3

Perfect score: 66
Sequence: 1 cagcgcgcgcgcgcgcgcgcac.....ctgctctcttctgaagta 66

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 17 seqs, 348 residues

Total number of hits satisfying chosen parameters: 34

Minimum DB seq length: 15
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 17 summaries

Database : us-10-619-253-3_2989_3054.rmpbns:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	Score	Query Match	Length	ID	Description
1	25	37.9	25	1	US-11-121-849-244253, Sequence 244253, App
2	21	31.8	21	1	US-10-923-451-798, Sequence 798, App
3	21	31.8	21	1	US-10-923-451-800, Sequence 800, App
4	21	31.8	21	1	US-10-923-451-802, Sequence 802, App
5	21	31.8	21	1	US-10-923-451-804, Sequence 804, App
6	21	31.8	21	1	US-10-923-451-805, Sequence 805, App
7	20	30.3	20	1	US-10-923-451-805, Sequence 350262, App
8	20	30.3	21	1	US-10-923-451-799, Sequence 799, App
9	20	30.3	21	1	US-10-923-451-801, Sequence 801, App
10	20	30.3	21	1	US-10-923-451-803, Sequence 803, App
11	20	30.3	21	1	US-10-923-451-806, Sequence 806, App
12	19	28.8	19	1	US-10-923-451-167, Sequence 167, App
13	19	28.8	19	1	US-10-923-451-168, Sequence 168, App
14	19	28.8	19	1	US-10-923-451-169, Sequence 169, App
15	19	28.8	19	1	US-10-923-451-457, Sequence 457, App
16	19	28.8	19	1	US-10-923-451-458, Sequence 458, App
17	19	28.8	19	1	US-10-923-451-459, Sequence 459, App

ALIGNMENTS

RESULT 1
US-11-121-849-244253
Sequence 244253, Application US/11121849
Publication No. US20050272080A1
GENERAL INFORMATION:
APPLICANT: John Palma
TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded s
FILE REFERENCE: 3684.1
CURRENT APPLICATION NUMBER: US/11/121, 849
CURRENT FILING DATE: 2003-05-03

PRIOR APPLICATION NUMBER: 60/567,949
PRIOR FILING DATE: 2004-05-03
NUMBER OF SEQ ID NOS: 673904
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 244253
LENGTH: 25
TYPE: DNA
ORGANISM: Homo sapien
US-11-121-849-244253

Query Match 37.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 3016 GCTCAGGTCACCTGAAACCACTGCTT 3040
Db 1 GCTCAGGTCACCTGAAACCACTGCTT 25

RESULT 2
US-10-923-451-798
Sequence 798, Application US/10923451
Publication No. US20050256068A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwigen, James
APPLICANT: Thompson, James
APPLICANT: Belgeiman, Leonid
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Stearoyl-CoA Desaturase
FILE REFERENCE: 400/210 (MBH02-1030-C)
CURRENT APPLICATION NUMBER: US/10/923,451
CURRENT FILING DATE: 2004-08-20
NUMBER OF SEQ ID NOS: 810
SOFTWARE: PatentIn version 3.3
SEQ ID NO 798
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)-(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety, inverted abasic.
OTHER INFORMATION: Inverted nucleotide or other terminal cap that is optionally prese
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)-(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety, inverted abasic,
OTHER INFORMATION: Inverted nucleotide or other terminal cap that is optionally prese
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)-(20)
OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide Linkage
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)-(19)
OTHER INFORMATION: RNA
US-10-923-451-798

Query Match 31.8%; Score 21; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 4.2;
Matches 14; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Oy 3027 CTGAACCACTGCTCTCTCTTTT 3047
Db 1 CTGAACCACTGCTCTCTCTTTT 21

RESULT 3
US-10-923-451-800
Sequence 800, Application US/10923451

```
Publication No. US20050256068A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwiggen, James
APPLICANT: Thompson, James
APPLICANT: Beigelman, Leonid
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Stearoyl-CoA Desaturase
FILE REFERENCE: 400/210 (MBH02-1030-C)
CURRENT APPLICATION NUMBER: US/10/923,451
CURRENT FILING DATE: 2004-08-20
NUMBER OF SEQ ID NOS: 810
SOFTWARE: PatentIn version 3.3
SEQ ID NO 800
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(5)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8)..(8)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(11)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(7)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (9)..(10)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (12)..(19)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(19)
OTHER INFORMATION: RNA
US-10-923-451-800

Query Match      31.8%; Score 21; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 4.2;
Matches 14; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY      3027 CTGAACCACTGCTCTCTTT 3047
Db      1 CUGAACCACTGCTCTCTTT 21

RESULT 4
US-10-923-451-802
Sequence 802, Application US/10923451
Publication No. US20050256068A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwiggen, James
APPLICANT: Thompson, James
APPLICANT: Beigelman, Leonid
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Stearoyl-CoA Desaturase
FILE REFERENCE: 400/210 (MBH02-1030-C)
CURRENT APPLICATION NUMBER: US/10/923,451
CURRENT FILING DATE: 2004-08-20
NUMBER OF SEQ ID NOS: 810
SOFTWARE: PatentIn version 3.3
SEQ ID NO 800
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(5)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8)..(8)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(11)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(7)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (9)..(10)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (12)..(19)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(19)
OTHER INFORMATION: RNA
US-10-923-451-800
```

```
FILE REFERENCE: 400/210 (MBH02-1030-C)
CURRENT APPLICATION NUMBER: US/10/923,451
CURRENT FILING DATE: 2004-08-20
NUMBER OF SEQ ID NOS: 810
SOFTWARE: PatentIn version 3.3
SEQ ID NO 802
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(7)
OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (9)..(10)
OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (12)..(19)
OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety, inverted abasic,
OTHER INFORMATION: inverted nucleotide or other terminal cap that is optionally prese
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety, inverted abasic,
OTHER INFORMATION: inverted nucleotide or other terminal cap that is optionally prese
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(19)
OTHER INFORMATION: RNA
US-10-923-451-802

Query Match      31.8%; Score 21; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 4.2;
Matches 14; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY      3027 CTGAACCACTGCTCTCTTT 3047
Db      1 CUGAACCACTGCTCTCTTT 21

RESULT 5
US-10-923-451-804
Sequence 804, Application US/10923451
Publication No. US20050256068A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwiggen, James
APPLICANT: Thompson, James
APPLICANT: Beigelman, Leonid
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Stearoyl-CoA Desaturase
FILE REFERENCE: 400/210 (MBH02-1030-C)
CURRENT APPLICATION NUMBER: US/10/923,451
CURRENT FILING DATE: 2004-08-20
NUMBER OF SEQ ID NOS: 810
SOFTWARE: PatentIn version 3.3
SEQ ID NO 804
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
```

```
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(5)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8)..(8)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(11)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(2)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(7)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (9)..(10)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (12)..(19)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety, inverted abasic.
OTHER INFORMATION: Inverted nucleotide or other terminal cap that is optionally pre
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety, inverted abasic.
OTHER INFORMATION: Inverted nucleotide or other terminal cap that is optionally pre
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(19)
OTHER INFORMATION: RNA
US-10-923-451-804

Query Match 31.8%; Score 21; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 4.2;
Matches 14; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 3027 CTGAACCACTGCTCTCTTTT 3047
Db 1 CUGAACCACTGCTCTCTTTT 21

RESULT 6
US-10-923-451-805
Sequence 805, Application US/10923451
Publication No. US20050256068A1
GENERAL INFORMATION:
APPLICANT: Sitma Therapeutics, Inc.
APPLICANT: MCSwigen, James
APPLICANT: Thompson, James
APPLICANT: Beigelman, Leonid
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Stearoyl-CoA Desaturase
FILE REFERENCE: 400/210 (MHB02-1030-C)
CURRENT APPLICATION NUMBER: US/10/923,451
CURRENT FILING DATE: 2004-08-20
NUMBER OF SEQ ID NOS: 810
SOFTWARE: PatentIn version 3.3
SEQ ID NO 805
LENGTH: 21
TYPE: DNA
```

```
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(7)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (9)..(10)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (12)..(19)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety, inverted abasic.
OTHER INFORMATION: Inverted nucleotide or other terminal cap that is optionally pre
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety, inverted abasic.
OTHER INFORMATION: Inverted nucleotide or other terminal cap that is optionally pre
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(19)
OTHER INFORMATION: RNA
US-10-923-451-805

Query Match 31.8%; Score 21; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 4.2;
Matches 14; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 3027 CTGAACCACTGCTCTCTTTT 3047
Db 1 CUGAACCACTGCTCTCTTTT 21

RESULT 7
US-10-310-914A-350262/c
Sequence 350262, Application US/10310914A
Publication No. US2006003322A1
GENERAL INFORMATION:
APPLICANT: Bentwich, Isaac
APPLICANT: Shlier, Kuzat
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310,914A
CURRENT FILING DATE: 2002-12-06
NUMBER OF SEQ ID NOS: 1388402
SOFTWARE: PatentIn version 3.3
SEQ ID NO 350262
LENGTH: 20
TYPE: RNA
ORGANISM: Human
US-10-310-914A-350262

Query Match 30.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3035 CTGCTTCTCTTTTGAAGTA 3054
Db 20 CTGCTTCTCTTTTGAAGTA 1
```

```
RESULT 8
US-10-923-451-799/c
/ Sequence 799, Application US/10923451
/ Publication No. US20050256068A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: MCSwigen, James
/ APPLICANT: Thompson, James
/ APPLICANT: Beigelman, Leonid
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Stearoyl-CoA Desaturase
/ TITLE OF INVENTION: (SCD) Gene Expression Using Short Interfering Nucleic Acid (siNA)
/ FILE REFERENCE: 400/210 (MBHB02-1030-C)
/ CURRENT APPLICATION NUMBER: US/10/923,451
/ NUMBER OF SEQ ID NOS: 810
/ SOFTWARE: Patentin version 3.3
/ SEQ ID NO 799
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Synthetic
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide Linkage
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(19)
/ OTHER INFORMATION: RNA
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 3'-3 attached terminal glyceryl moiety or inverted deoxyribose (or
US-10-923-451-799

Query Match
Best Local Similarity 30.3%; Score 20; DB 1; Length 21;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3026 ACTGAACCACTGCTCTCTT 3045
Db 20 ACTGAACCACTGCTCTCTT 1

RESULT 9
US-10-923-451-801/c
/ Sequence 801, Application US/10923451
/ Publication No. US20050256068A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: MCSwigen, James
/ APPLICANT: Thompson, James
/ APPLICANT: Beigelman, Leonid
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Stearoyl-CoA Desaturase
/ TITLE OF INVENTION: (SCD) Gene Expression Using Short Interfering Nucleic Acid (siNA)
/ FILE REFERENCE: 400/210 (MBHB02-1030-C)
/ CURRENT APPLICATION NUMBER: US/10/923,451
/ NUMBER OF SEQ ID NOS: 810
/ SOFTWARE: Patentin version 3.3
/ SEQ ID NO 801
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Synthetic
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(8)
/ OTHER INFORMATION: 2'-O-Methyl
/ FEATURE:
/ NAME/KEY: misc_feature
```

```
LOCATION: (10)..(11)
/ OTHER INFORMATION: 2'-O-Methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (13)..(14)
/ OTHER INFORMATION: 2'-O-Methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (18)..(19)
/ OTHER INFORMATION: 2'-O-Methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (9)..(9)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (12)..(12)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (15)..(17)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(19)
/ OTHER INFORMATION: RNA
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 3'-3 attached terminal glyceryl moiety or inverted deoxyribose (or
US-10-923-451-801

Query Match
Best Local Similarity 30.3%; Score 20; DB 1; Length 21;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3026 ACTGAACCACTGCTCTCTT 3045
Db 20 ACTGAACCACTGCTCTCTT 1

RESULT 10
US-10-923-451-803/c
/ Sequence 803, Application US/10923451
/ Publication No. US20050256068A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: MCSwigen, James
/ APPLICANT: Thompson, James
/ APPLICANT: Beigelman, Leonid
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Stearoyl-CoA Desaturase
/ TITLE OF INVENTION: (SCD) Gene Expression Using Short Interfering Nucleic Acid (siNA)
/ FILE REFERENCE: 400/210 (MBHB02-1030-C)
/ CURRENT APPLICATION NUMBER: US/10/923,451
/ NUMBER OF SEQ ID NOS: 810
/ SOFTWARE: Patentin version 3.3
/ SEQ ID NO 803
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Synthetic
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (9)..(9)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (12)..(12)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
```

```
LOCATION: (15)..(17)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(19)
OTHER INFORMATION: RNA
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide Linkage
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal glyceryl moiety or inverted deoxyabasic (d
US-10-923-451-803

Query Match 30.3%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3026 ACTGAACCACTGCTTCTCTT 3045
DB 20 ACTGAACCACTGCTTCTCTT 1

RESULT 11
US-10-923-451-806/c
Sequence 806, Application US/10923451
Publication No. US20050256068A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwiggen, James
APPLICANT: Thompson, James
APPLICANT: Beigelman, Leonid
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Stearoyl-CoA Desaturase
TITLE OF INVENTION: (SCD) Gene Expression Using Short Interfering Nucleic Acid (siNA)
FILE REFERENCE: 400/210 (MBH02-1030-C)
CURRENT APPLICATION NUMBER: US/10/923,451
CURRENT FILING DATE: 2004-08-20
NUMBER OF SEQ ID NOS: 810
SOFTWARE: PatentIn version 3.3
SEQ ID NO 806
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(8)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(11)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(14)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (9)..(9)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (12)..(12)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
```

```
LOCATION: (15)..(17)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(19)
OTHER INFORMATION: RNA
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide Linkage
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal glyceryl moiety or inverted deoxyabasic (d
US-10-923-451-806

Query Match 30.3%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3026 ACTGAACCACTGCTTCTCTT 3045
DB 20 ACTGAACCACTGCTTCTCTT 1

RESULT 12
US-10-923-451-167
Sequence 167, Application US/10923451
Publication No. US20050256068A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwiggen, James
APPLICANT: Thompson, James
APPLICANT: Beigelman, Leonid
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Stearoyl-CoA Desaturase
TITLE OF INVENTION: (SCD) Gene Expression Using Short Interfering Nucleic Acid (siNA)
FILE REFERENCE: 400/210 (MBH02-1030-C)
CURRENT APPLICATION NUMBER: US/10/923,451
CURRENT FILING DATE: 2004-08-20
NUMBER OF SEQ ID NOS: 810
SOFTWARE: PatentIn version 3.3
SEQ ID NO 167
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
US-10-923-451-167

Query Match 28.8%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.8;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2991 GGCAGCTCCCTCCGACCA 3009
DB 1 GGCAGCTCCCTCCGACCA 19

RESULT 13
US-10-923-451-168
Sequence 168, Application US/10923451
Publication No. US20050256068A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwiggen, James
APPLICANT: Thompson, James
APPLICANT: Beigelman, Leonid
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Stearoyl-CoA Desaturase
TITLE OF INVENTION: (SCD) Gene Expression Using Short Interfering Nucleic Acid (siNA)
FILE REFERENCE: 400/210 (MBH02-1030-C)
CURRENT APPLICATION NUMBER: US/10/923,451
CURRENT FILING DATE: 2004-08-20
NUMBER OF SEQ ID NOS: 810
```

```
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 168
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic
US-10-923-451-168

Query Match
  28.8%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.8;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 3009 ACAGAAATGCTCAGGCTCAC 3027
  |||||:|||||1||
  1 ACAGAAUCCUCACAGGCTCAC 19

RESULT 14
US-10-923-451-169
/ Sequence 169, Application US/10923451
/ Publication No. US20050256068A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwigen, James
/ APPLICANT: Thompson, James
/ APPLICANT: Beigelman, Leonid
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Stearoyl-CoA Desaturase
/ FILE REFERENCE: 400/210 (MHB02-1030-C)
/ CURRENT APPLICATION NUMBER: US/10/923,451
/ CURRENT FILING DATE: 2004-08-20
/ NUMBER OF SEQ ID NOS: 810
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 169
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic
US-10-923-451-169

Query Match
  28.8%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 6.8;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 3027 CTGAACCACTGCTTCTT 3045
  |||||:|||||:|||||:
  1 CUGAACCACTGCTTCTT 19

RESULT 15
US-10-923-451-457/c
/ Sequence 457, Application US/10923451
/ Publication No. US20050256068A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwigen, James
/ APPLICANT: Thompson, James
/ APPLICANT: Beigelman, Leonid
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Stearoyl-CoA Desaturase
/ FILE REFERENCE: 400/210 (MHB02-1030-C)
/ CURRENT APPLICATION NUMBER: US/10/923,451
/ CURRENT FILING DATE: 2004-08-20
/ NUMBER OF SEQ ID NOS: 810
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 457
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic
```

```
US-10-923-451-457

Query Match
  28.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.8;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2991 GGCAGCTCCCTCCGACCA 3009
  |||||:|||||:|||||:
  19 GGCAGCTCCCTCCGACCA 1

RESULT 16
US-10-923-451-458/c
/ Sequence 458, Application US/10923451
/ Publication No. US20050256068A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwigen, James
/ APPLICANT: Thompson, James
/ APPLICANT: Beigelman, Leonid
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Stearoyl-CoA Desaturase
/ FILE REFERENCE: 400/210 (MHB02-1030-C)
/ CURRENT APPLICATION NUMBER: US/10/923,451
/ CURRENT FILING DATE: 2004-08-20
/ NUMBER OF SEQ ID NOS: 810
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 458
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic
US-10-923-451-458

Query Match
  28.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.8;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3009 ACAGAAATGCTCAGGCTCAC 3027
  |||||:|||||:|||||:
  19 ACAGAAATGCTCAGGCTCAC 1

RESULT 17
US-10-923-451-459/c
/ Sequence 459, Application US/10923451
/ Publication No. US20050256068A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwigen, James
/ APPLICANT: Thompson, James
/ APPLICANT: Beigelman, Leonid
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Stearoyl-CoA Desaturase
/ FILE REFERENCE: 400/210 (MHB02-1030-C)
/ CURRENT APPLICATION NUMBER: US/10/923,451
/ CURRENT FILING DATE: 2004-08-20
/ NUMBER OF SEQ ID NOS: 810
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 459
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic
US-10-923-451-459

Query Match
  28.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.8;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3027 CTGAACCACTGCTTCTT 3045
```


Db 19 CTGACCACTGCTTCTT 1

Search completed: March 27, 2006, 08:31:14
Job time : 0.001 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 27, 2006, 08:30:11 ; Search time 0.001 Seconds
(without alignments)
13.200 Million cell updates/sec

Title: US-10-619-253-3

Perfect score: 66
Sequence: 1 cagcgagctccctcctgcac.....ctgcttcctttggaagaa 66

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 5 segs, 100 residues

Total number of hits satisfying chosen parameters: 10

Minimum DB seq length: 15

Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 5 summaries

Database : us-10-619-253-3_2989_3054.rnpbm4:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	No.	Score	Match	Length	DB	ID	Description
C 1	20	30.3	20	1	US-09-918-187-30	Appl	Sequence 30, Appl
C 2	20	30.3	20	1	US-10-484-442-30	Appl	Sequence 30, Appl
C 3	20	30.3	20	1	US-10-619-253-30	Appl	Sequence 30, Appl
C 4	20	30.3	20	1	US-10-619-253-124	App	Sequence 124, App
C 5	20	30.3	20	1	US-10-619-253-125	App	Sequence 125, App

ALIGNMENTS

RESULT 1
US-09-918-187-30/c

; Sequence 30, Application US/09918187
; Publication No. US20030083282A1

; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke

; TITLE OF INVENTION: ANTISENSE MODULATION OF STEAROYL-CoA DESATURASE EXPRESSION
; FILE REFERENCE: ISPH-0590

; CURRENT APPLICATION NUMBER: US/09/918,187
; CURRENT FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 80

; SEQ ID NO 30

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide

US-09-918-187-30

Query Match 30.3%, Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3011 AGAATGCTCAGGTCACCTGA 3030
Db 20 AGAATGCTCAGGTCACCTGA 1

RESULT 2

US-10-484-442-30/c

; Sequence 30, Application US/10484442
; Publication No. US20040254359A1

; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.

; TITLE OF INVENTION: ANTISENSE MODULATION OF STEAROYL-CoA DESATURASE EXPRESSION
; FILE REFERENCE: ISPH70695

; CURRENT APPLICATION NUMBER: US/10/484,442
; CURRENT FILING DATE: 2004-01-29

; PRIOR APPLICATION NUMBER: 09/918,187
; PRIOR FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 80

; SEQ ID NO 30

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide

US-10-484-442-30

Query Match 30.3%, Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3011 AGAATGCTCAGGTCACCTGA 3030
Db 20 AGAATGCTCAGGTCACCTGA 1

RESULT 3

US-10-619-253-30/c

; Sequence 30, Application US/10619253
; Publication No. US20050043256A1

; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke

; TITLE OF INVENTION: ANTISENSE MODULATION OF STEAROYL-CoA DESATURASE EXPRESSION
; FILE REFERENCE: ISPH-0590US.P1

; CURRENT APPLICATION NUMBER: US/10/619,253
; CURRENT FILING DATE: 2003-07-15

; PRIOR APPLICATION NUMBER: US 09/918,187
; PRIOR FILING DATE: 2001-07-30

; NUMBER OF SEQ ID NOS: 418

; SEQ ID NO 30

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide

US-10-619-253-30

Query Match 30.3%, Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3011 AGAATGCTCAGGTCACCTGA 3030
Db 20 AGAATGCTCAGGTCACCTGA 1

RESULT 4

US-10-619-253-124/c
; Sequence 124, Application US/10619253
; Publication No. US20050043256A1

```
/ GENERAL INFORMATION:
/ APPLICANT: Rosanne M. Crooke
/ APPLICANT: Mark J. Graham
/ TITLE OF INVENTION: ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION
/ FILE REFERENCE: ISPH-0590US.PI
/ CURRENT APPLICATION NUMBER: US/10/619,253
/ CURRENT FILING DATE: 2003-07-15
/ PRIOR APPLICATION NUMBER: US 09/918,187
/ PRIOR FILING DATE: 2001-07-30
/ NUMBER OF SEQ ID NOS: 418
/ SEQ ID NO 124
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-619-253-124

Query Match      30.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.1.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3020 AGGCTCACTGAACCACTGCT 3039
Db      20 AGGCTCACTGAACCACTGCT 1
|||||
|||||

RESULT 5
US-10-619-253-125/C
/ Sequence 125, Application US/10619253
/ Publication No. US20050043256A1
/ GENERAL INFORMATION:
/ APPLICANT: Rosanne M. Crooke
/ APPLICANT: Mark J. Graham
/ TITLE OF INVENTION: ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION
/ FILE REFERENCE: ISPH-0590US.PI
/ CURRENT APPLICATION NUMBER: US/10/619,253
/ CURRENT FILING DATE: 2003-07-15
/ PRIOR APPLICATION NUMBER: US 09/918,187
/ PRIOR FILING DATE: 2001-07-30
/ NUMBER OF SEQ ID NOS: 418
/ SEQ ID NO 125
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-619-253-125

Query Match      30.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.1.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3035 CTGCTTCTCTTTGAAAGTA 3054
Db      20 CTGCTTCTCTTTGAAAGTA 1
|||||
|||||
```

Search completed: March 27, 2006, 08:30:11
Job time : 0.001 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 27, 2006, 08:28:37 ; Search time 0.001 Seconds
(without alignments)
61.908 Million cell updates/sec

Title: us-10-619-253-3

Perfect score: 66
Sequence: 1 caggcagctccctccgcac.....ctgctctcttgcgaagta 66

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 0.5

Searched: 23 seqs, 469 residues

Total number of hits satisfying chosen parameters: 46

Minimum DB seq length: 15
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 23 summaries

Database : us-10-619-253-3_2989_3054.rng4:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	21	31.8	21	1	ADBE27671 Stearoyl-CoA desat
2	21	31.8	21	1	ADBE27667 Stearoyl-CoA desat
3	21	31.8	21	1	ADBE27669 Stearoyl-CoA desat
4	20	30.3	20	1	ABE277075 Human Stearoyl-CoA
5	20	30.3	20	1	ADX18221 Human Stearoyl-CoA
6	20	30.3	20	1	ADX18220 Human Stearoyl-CoA
7	20	30.3	20	1	ADX18126 Human Stearoyl-CoA
8	20	30.3	21	1	ADBE27674 Stearoyl-CoA desat
9	20	30.3	21	1	ADBE27670 Stearoyl-CoA desat
10	20	30.3	21	1	ADBE27672 Stearoyl-CoA desat
11	20	30.3	21	1	ADBE27675 Stearoyl-CoA desat
12	20	30.3	21	1	AD014557 Human Interleukin-
13	20	30.3	21	1	AD014557 Human Interleukin-
14	20	30.3	21	1	AD014560 Human Interleukin-
15	20	30.3	21	1	AD014555 Human Interleukin-
16	20	30.3	22	1	ADBE27666 Stearoyl-CoA desat
17	20	30.3	22	1	ADBE27668 Stearoyl-CoA desat
18	19	28.8	19	1	ADBE27514 Stearoyl-CoA desat
19	19	28.8	19	1	ADBE27225 Stearoyl-CoA desat
20	19	28.8	19	1	ADBE27223 Stearoyl-CoA desat
21	19	28.8	19	1	ADBE27513 Stearoyl-CoA desat
22	19	28.8	19	1	ADBE27224 Stearoyl-CoA desat
23	19	28.8	19	1	ADBE27515 Stearoyl-CoA desat

ALIGNMENTS

RESULT 1
ADE27671
ID ADE27671 standard; RNA; 21 BP.
XX
AC ADE27671;

XX 29-JAN-2004 (first entry)
DT Stearoyl-CoA desaturase sRNA oligonucleotide SEQ ID NO:626.
XX
DE short interfering nucleic acid; sRNA; downregulation; inhibition; SCD;
XX Stearoyl-CoA desaturase; RNA interference; anorectic; antidiabetic;
KW antiarteriosclerotic; cyostatic; virocidic; obesity; diabetes;
KW atherosclerosis; cancer; viral infection; drug screening;
KW genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
PN W02003070885-A2.
XX
PD 28-AUG-2003.
XX
PF 13-FEB-2003; 2003WO-US004317.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 20-SEP-2002; 2002US-0412304P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcawiggen J, Beigelman L, Thompson J;
XX WPI; 2003-721687/68.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of obesity or diabetes, downregulates expression of the
PT Stearoyl-CoA desaturase gene.
XX
PS Disclosure; SEQ ID NO 626; 139pp; English.
XX
CC The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of the SCD (stearoyl-CoA desaturase) gene
CC by RNA interference. Also described: (1) modulating expression of SCD
CC genes in cells, tissue explants or organisms by introduction of siNA; (2)
CC kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
CC complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
CC siNAs have anorectic, antidiabetic, antiarteriosclerotic, cyostatic and
CC virocidic activities. The siNAs can be used to modulate expression of SCD
CC genes, in cells, tissue explants or organisms, e.g. for treating obesity;
CC diabetes (types I and II), atherosclerosis; cancer and viral infections.
CC They can also be used for drug screening, diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents an SCD siNA, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 7 C; 2 G; 2 T; 7 U; 0 Other;
XX
QY Query Match 31.8%; Score 21; DB 1; Length 21;
QY Best Local Similarity 66.7%; Pred. No. 5.4;
QY Matches 14; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
DB 3027 CTGAACCACTGCTTCTTTT 3047
DB 1 CUGAACCACTGCTTCTTTT 21
XX
RESULT 2
ADE27667
ID ADE27667 standard; RNA; 21 BP.
XX
AC ADE27667;

DT 29-JAN-2004 (first entry)
XX Stearoyl-CoA desaturase siNA oligonucleotide SEQ ID NO:622.
DE
XX
XX short interfering nucleic acid, siNA, downregulation; inhibition; SCD;
KM stearoyl-CoA desaturase; RNA interference; anorectic; antidiabetic;
KM antiarteriosclerotic; cytoskeletal; virocidic; obesity; diabetes;
KM atherosclerosis; cancer; viral infection; drug screening;
KM genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
XX WO2003070885-A2.
XX
XX 28-AUG-2003.
XX
XX 13-FEB-2003; 2003WO-US004317.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 20-SEP-2002; 2002US-0412304P.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Belgelman L, Thompson J;
PI
XX MPI; 2003-721687/68.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of obesity or diabetes, downregulates expression of the
PT stearoyl-CoA desaturase gene.
XX
XX
XX Disclosure; SEQ ID NO 622; 139pp; English.
XX
XX The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of the SCD (stearoyl-CoA desaturase) gene
CC by RNA interference. Also described: (1) modulating expression of SCD
CC genes in cells, tissue explants or organisms by introduction of siNA; (2)
CC kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
CC complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
CC siNA have anorectic, antidiabetic, antiarteriosclerotic, cytoskeletal
CC and virocidic activities. The siNAs can be used to modulate expression of SCD
CC genes, in cells, tissue explants or organisms, e.g. for treating obesity;
CC diabetes (types I and II); atherosclerosis; cancer and viral infections.
CC They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents an SCD siNA, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 7 C; 2 G; 2 T; 7 U; 0 Other;
XX
Query Match 31.8%; Score 21; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 5.4;
Matches 14; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
QY 3027 CTGAACCACTGCTCTCTTTT 3047
DB 1 CUGAACCACTGCTCTCTTTT 21

XX Stearoyl-CoA desaturase siNA oligonucleotide SEQ ID NO:624.
DE
XX
XX short interfering nucleic acid, siNA, downregulation; inhibition; SCD;
KM stearoyl-CoA desaturase; RNA interference; anorectic; antidiabetic;
KM antiarteriosclerotic; cytoskeletal; virocidic; obesity; diabetes;
KM atherosclerosis; cancer; viral infection; drug screening;
KM genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
XX WO2003070885-A2.
XX
XX 28-AUG-2003.
XX
XX 13-FEB-2003; 2003WO-US004317.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 20-SEP-2002; 2002US-0412304P.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Belgelman L, Thompson J;
PI
XX MPI; 2003-721687/68.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of obesity or diabetes, downregulates expression of the
PT stearoyl-CoA desaturase gene.
XX
XX
XX Disclosure; SEQ ID NO 624; 139pp; English.
XX
XX The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of the SCD (stearoyl-CoA desaturase) gene
CC by RNA interference. Also described: (1) modulating expression of SCD
CC genes in cells, tissue explants or organisms by introduction of siNA; (2)
CC kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
CC complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
CC siNA have anorectic, antidiabetic, antiarteriosclerotic, cytoskeletal
CC and virocidic activities. The siNAs can be used to modulate expression of SCD
CC genes, in cells, tissue explants or organisms, e.g. for treating obesity;
CC diabetes (types I and II); atherosclerosis; cancer and viral infections.
CC They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents an SCD siNA, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 7 C; 2 G; 2 T; 7 U; 0 Other;
XX
Query Match 31.8%; Score 21; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 5.4;
Matches 14; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
QY 3027 CTGAACCACTGCTCTCTTTT 3047
DB 1 CUGAACCACTGCTCTCTTTT 21

RESULT 4
AB277075/c
ID AB277075 standard; DNA, 20 BP.
XX
XX AB277075;
AC
XX
XX 07-MAY-2003 (first entry)
DT
XX

DE	Human stearyl-CoA desaturase phosphorothioate oligonucleotide SEQ.30.
XX	Human; stearyl-CoA desaturase; phosphorothioate; 2'-O-methoxyethyl;
KW	2'-MOE; cardiovascular; antiarteriosclerotic; antilipemic; cytostatic;
KV	antiinflammatory; antisense therapy; antisense oligonucleotide; tumour;
KX	abnormal lipid metabolism; abnormal cholesterol metabolism; infection;
XX	atherosclerosis; cardiovascular disease; inflammation; inhibition; ss.
OS	Homo sapiens.
XX	Synthetic.
FT	Key
FT	Location/Qualifiers
FT	modified_base
FT	1..20
FT	/+tag= a
FT	/mod_base= OTHER
FT	/note= "phosphorothioate linkages"
FT	modified_base
FT	1..5
FT	/+tag= b
FT	/mod_base= OTHER
FT	/note= "2'-O-methoxyethyl (2'-MOE) gapmer"
FT	modified_base
FT	16..20
FT	/+tag= c
FT	/mod_base= OTHER
FT	/note= "2'-O-methoxyethyl (2'-MOE) gapmer"
PN	WO2003012031-A2.
PD	13-FEB-2003.
XX	
PP	16-JUL-2002; 2002WO-US022676.
PR	30-JUN-2001; 2001US-00918187.
PA	(ISIS-) ISIS PHARM INC.
PI	Crooke RM, Graham MJ;
DR	WP1; 2003-248160/24.
XX	
PT	New antisense oligonucleotides targeted to nucleic acids encoding human stearyl-CoA desaturase, useful for treating diseases associated with the desaturase, e.g. atherosclerosis, and in diagnostic and research applications.
XX	
PS	Claim 3; Page 94; 117pp; English.
CC	The present invention describes a compound (I) that is 8-50 nucleobases in length targeted to a nucleic acid molecule encoding human stearyl-CoA desaturase, and which specifically hybridises with and inhibits the expression of human stearyl-CoA desaturase, or which specifically hybridises with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding human stearyl-CoA desaturase. Human stearyl-CoA desaturase is mapped to chromosome 10. (I) has antilipemic, cardiovascular, antiarteriosclerotic, cytostatic and antiinflammatory activities, and can be used in antisense therapy. The antisense compounds (I) can be used for modulating the expression of human stearyl-CoA desaturase and for treating diseases or conditions associated with expression of human stearyl-CoA desaturase, e.g. abnormal lipid or cholesterol metabolism, arteriosclerosis, or cardiovascular diseases. The antisense compounds (I) can also be used for diagnostics, therapeutics and prophylaxis, e.g. to prevent or delay infection, inflammation or tumour formation, as research reagents and kits, and in distinguishing between functions of various members of a biological pathway. The present sequence represents a human stearyl-CoA desaturase inhibiting chimeric phosphorothioate antisense oligonucleotide, which is given in an example from the present invention
SO	Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
Query Match	30.3%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred.No. 6.9;
Matches 20; Conservative 0;	Mismatches 0; Indels 0; Gaps 0;

OY	3011	AGAAATGCTCAGGGCTCACTGA	3030
Db	20	AGAAATGCTCAGGGCTCACTGA	1
RESULT 5			
ID	ADXI18221/c		
XX	ADXI18221	standard; DNA; 20 BP.	
AC			
XX	ADXI18221;		
DT	05-MAY-2005	(first entry)	
XX			
DE	Human Stearoyl-CoA desaturase antisense oligonucleotide ISIS 300912.		
XX			
KW	Antisense; gene therapy; Stearoyl-CoA desaturase; hypertension;		
KM	hypotenstive; non-insulin dependent diabetes; antidiabetic;		
KM	hypocretine disease; gastrointestinal disease; metabolic disorder; cancer;		
KW	cyclostatic; neoplasm; obesity; anorectic; nutritional disorder;		
KM	Cardiovascular disease; Dermatological disease; Immune disorder;		
XX	Neurological disease; ss.		
XX			
OS	Homo sapiens.		
OS	Synthetic.		
XX			
PN	WO2005014607-A2.		
XX			
PD	17-FEB-2005.		
XX			
PF	15-JUL-2004; 2004WO-US018932.		
XX			
PR	15-JUL-2003; 2003US-00619253.		
XX			
PA	(ISIS-) ISIS PHARM INC.		
XX			
PI	Crooke RM, Graham MJ;		
XX			
DR	WPI; 2005-163213/17.		
XX			
PT	New compound comprising 8-50 nucleobases targeted to a nucleic acid		
PT	molecule encoding stearoyl-CoA desaturase, useful in preparing a		
PT	composition for treating a condition associated with stearoyl-CoA		
PT	desaturase, e.g., obesity.		
XX			
PS	Claim 1; SEQ ID NO 125; 256bp; English.		
XX			
CC	The invention relates to a new compound, which is targeted to a nucleic		
CC	acid molecule encoding stearoyl-CoA desaturase and inhibits its		
CC	expression. The compound is useful in preparing a composition for		
CC	treating an animal having a disease or condition associated with stearoyl		
CC	-CoA desaturase, e.g. cardiovascular disorder, obesity, non-insulin-		
CC	dependent diabetes mellitus, a skin disease, hypertension, a neurological		
CC	disease, an immune disorder or cancer. The present sequence represents a		
CC	human stearoyl-CoA desaturase antisense oligonucleotide.		
XX			
QO	Sequence 20 BP; 9 A; 3 C; 4 G; 4 T; 0 U; 0 Other;		
XX			
QY	Query Match	30.3%; Score 20; DB 1; Length 20;	
	Best Local Similarity	100.0%; Pred. No. 6.9;	
	Matches 20; Conservative	0; Mismatches	0; Gaps
DB	3035	CGGCTTCCTCTTGAAGA	3054
	20	CGGCTTCCTCTTGAAGA	1
RESULT 6			
ID	ADXI18220/c		
XX	ADXI18220	standard; DNA; 20 BP.	
AC			
XX	ADXI18220;		
DT	05-MAY-2005	(first entry)	

```
XX DE Human Stearoyl-CoA desaturase antisense oligonucleotide ISIS 300911.
XX KM Antisense; gene therapy; Stearoyl-CoA desaturase; hypertension;
XX KM hypotensive; non-insulin dependent diabetes; antidiabetic;
XX KM endocrine disease; gastrointestinal disease; metabolic disorder; cancer;
XX KM cytostatic; neoplasm; obesity; anorectic; nutritional disorder;
XX KM Cardiovascular disease; Dermatological disease; Immune disorder;
XX KM Neurological disease; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2005014607-A2.
XX PD 17-FEB-2005.
XX PF 15-JUL-2004; 2004WO-US018932.
XX PR 15-JUL-2003; 2003US-00619253.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Crooke RM, Graham MJ;
XX DR WPI; 2005-163213/17.
XX DR
XX PT New compound comprising 8-50 nucleobases targeted to a nucleic acid
XX PT molecule encoding stearoyl-CoA desaturase, useful in preparing a
XX PT composition for treating a condition associated with stearoyl-CoA
XX PT desaturase, e.g., obesity.
XX PS Claim 1; SEQ ID NO 124; 256pp; English.
XX CC The invention relates to a new compound, which is targeted to a nucleic
XX CC acid molecule encoding stearoyl-CoA desaturase and inhibits its
XX CC expression. The compound is useful in preparing a composition for
XX CC treating an animal having a disease or condition associated with
XX CC stearoyl-CoA desaturase, e.g. cardiovascular disorder, obesity, non-insulin-
XX CC dependent diabetes mellitus, a skin disease, hypertension, a neurological
XX CC disease, an immune disorder or cancer. The present sequence represents a
XX CC human stearoyl-CoA desaturase antisense oligonucleotide.
XX SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 30.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 6.9;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 3020 AGGCTCACTGAACCACTGCT 3039
XX DB 20 AGGTCACCTGAACCACTGCT 1
XX
XX RESULT 7
XX ADX18126/c
XX ID ADX18126 standard; DNA; 20 BP.
XX AC ADX18126;
XX AC
XX ADX18126;
XX PD 05-MAY-2005 (first entry)
XX DE Human Stearoyl-CoA desaturase antisense oligonucleotide ISIS 147919.
XX KM Antisense; gene therapy; Stearoyl-CoA desaturase; hypertension;
XX KM hypotensive; non-insulin dependent diabetes; antidiabetic;
XX KM endocrine disease; gastrointestinal disease; metabolic disorder; cancer;
XX KM cytostatic; neoplasm; obesity; anorectic; nutritional disorder;
XX KM Cardiovascular disease; Dermatological disease; Immune disorder;
XX KM Neurological disease; ss.
XX OS Homo sapiens.
XX OS Synthetic.
```

```
XX PN WO2005014607-A2.
XX PD 17-FEB-2005.
XX PF 15-JUL-2004; 2004WO-US018932.
XX PR 15-JUL-2003; 2003US-00619253.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Crooke RM, Graham MJ;
XX DR WPI; 2005-163213/17.
XX DR
XX PT New compound comprising 8-50 nucleobases targeted to a nucleic acid
XX PT molecule encoding stearoyl-CoA desaturase, useful in preparing a
XX PT composition for treating a condition associated with stearoyl-CoA
XX PT desaturase, e.g., obesity.
XX PS Example 15; SEQ ID NO 30; 256pp; English.
XX CC The invention relates to a new compound, which is targeted to a nucleic
XX CC acid molecule encoding stearoyl-CoA desaturase and inhibits its
XX CC expression. The compound is useful in preparing a composition for
XX CC treating an animal having a disease or condition associated with
XX CC stearoyl-CoA desaturase, e.g. cardiovascular disorder, obesity, non-insulin-
XX CC dependent diabetes mellitus, a skin disease, hypertension, a neurological
XX CC disease, an immune disorder or cancer. The present sequence represents a
XX CC human stearoyl-CoA desaturase antisense oligonucleotide.
XX SQ Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 30.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 6.9;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 3011 AGAATCTCAGGCTCAGCA 3030
XX DB 20 AGAATCTCAGGCTCAGCA 1
XX
XX RESULT 8
XX ADE27674/c
XX ID ADE27674 standard; RNA; 21 BP.
XX AC ADE27674;
XX AC
XX DT 29-JAN-2004 (first entry)
XX DE Stearoyl-CoA desaturase siRNA oligonucleotide SEQ ID NO:629.
XX KM short interfering nucleic acid, siNA, downregulation; inhibition; SCD;
XX KM stearoyl-CoA desaturase; RNA interference; anorectic; diabetes;
XX KM antihypertensive; cytostatic; virucide; obesity; diabetes;
XX KM atherosclerosis; cancer; viral infection; drug screening;
XX KM genetic engineering; pharmacogenomic; gene mapping; ss.
XX OS Synthetic.
XX OS
XX PN WO2003070885-A2.
XX PD 28-AUG-2003.
XX DE 13-FEB-2003; 2003WO-US004317.
XX PF 20-FEB-2002; 2002US-0358580P.
XX PR 11-MAR-2002; 2002US-0363124P.
XX PR 06-JUN-2002; 2002US-0386782P.
XX PR 29-AUG-2002; 2002US-0406784P.
XX PR 05-SEP-2002; 2002US-0408378P.
XX PR 09-SEP-2002; 2002US-0409293P.
XX PR 20-SEP-2002; 2002US-0412304P.
```


PR 15-JAN-2003; 2003US-0440129P.
XX (RIBO-) RIBOZYME PHARM INC.
PA Mcswiggen J, Beigelman L, Thompson J;
XX WPI; 2003-721687/68.
DR
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of obesity or diabetes, downregulates expression of the
PT stearyl-CoA desaturase gene.
XX
PS Disclosure; SEQ ID NO 629; 139pp; English.
XX
XX The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of the SCD (stearyl-CoA desaturase) gene
CC by RNA interference. Also described: (1) modulating expression of SCD
CC genes in cells, tissue explants or organisms by introduction of siNA; (2)
CC kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
CC complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
CC siNAs have anorectic, antidiabetic, antiarteriosclerotic, cytostatic and
CC vinuclide activities. The siNAs can be used to modulate expression of SCD
CC genes, in cells, tissue explants or organisms, e.g. for treating obesity;
CC diabetes (types I and II), atherosclerosis; cancer and viral infections.
CC They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents an SCD siNA, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 21 BP; 7 A; 2 C; 7 G; 2 T; 3 U; 0 Other;
Query Match 30.3%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 6.6;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 3026 ACTGAACCACTGCTTCTT 3045
Db 20 ACTGAACCACTGCTTCTT 1
RESULT 9
ADE27670/C
ID ADE27670 standard; RNA; 21 BP.
XX
AC ADE27670;
XX
DT 29-JAN-2004 (first entry)
XX
DE Stearyl-CoA desaturase siNA oligonucleotide SEQ ID NO:625.
XX
XX short interfering nucleic acid; siNA; downregulation; inhibition; SCD;
KM stearyl-CoA desaturase; RNA interference; anorectic; antidiabetic;
KM antiarteriosclerotic; cytostatic; vinuclide; obesity; diabetes;
KM atherosclerosis; cancer; viral infection; drug screening;
KM genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
PN WO2003070885-A2.
XX
PD 28-AUG-2003.
XX
PF 13-FEB-2003; 2003WO-US004317.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 20-SEP-2002; 2002US-0412304P.
PR 15-JAN-2003; 2003US-0440129P.

XX (RIBO-) RIBOZYME PHARM INC.
PA Mcswiggen J, Beigelman L, Thompson J;
XX WPI; 2003-721687/68.
DR
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of obesity or diabetes, downregulates expression of the
PT stearyl-CoA desaturase gene.
XX
PS Disclosure; SEQ ID NO 625; 139pp; English.
XX
XX The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of the SCD (stearyl-CoA desaturase) gene
CC by RNA interference. Also described: (1) modulating expression of SCD
CC genes in cells, tissue explants or organisms by introduction of siNA; (2)
CC kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
CC complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
CC siNAs have anorectic, antidiabetic, antiarteriosclerotic, cytostatic and
CC vinuclide activities. The siNAs can be used to modulate expression of SCD
CC genes, in cells, tissue explants or organisms, e.g. for treating obesity;
CC diabetes (types I and II), atherosclerosis; cancer and viral infections.
CC They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents an SCD siNA, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 21 BP; 7 A; 2 C; 7 G; 2 T; 3 U; 0 Other;
Query Match 30.3%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 6.6;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 3026 ACTGAACCACTGCTTCTT 3045
Db 20 ACTGAACCACTGCTTCTT 1

RESULT 10
ADE27672/C
ID ADE27672 standard; RNA; 21 BP.
XX
AC ADE27672;
XX
DT 29-JAN-2004 (first entry)
XX
DE Stearyl-CoA desaturase siNA oligonucleotide SEQ ID NO:627.
XX
XX short interfering nucleic acid; siNA; downregulation; inhibition; SCD;
KM stearyl-CoA desaturase; RNA interference; anorectic; antidiabetic;
KM antiarteriosclerotic; cytostatic; vinuclide; obesity; diabetes;
KM atherosclerosis; cancer; viral infection; drug screening;
KM genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
PN WO2003070885-A2.
XX
PD 28-AUG-2003.
XX
PF 13-FEB-2003; 2003WO-US004317.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 20-SEP-2002; 2002US-0412304P.
PR 15-JAN-2003; 2003US-0440129P.

PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswiggen J, Beigelman L, Thompson J;
 XX
 DR WPI; 2003-721687/68.
 XX
 PT New short interfering nucleic acid, useful e.g. for treatment and
 PT diagnosis of obesity or diabetes, downregulates expression of the
 PT stearyl-CoA desaturase gene.
 XX
 PS Disclosure; SEQ ID NO 627; 139pp; English.
 XX
 CC The present invention describes a short interfering nucleic acid (siNA)
 CC that downregulates expression of the SCD (stearyl-CoA desaturase) gene
 CC by RNA interference. Also described: (1) modulating expression of SCD
 CC genes in cells, tissue explants or organisms by introduction of siNA; (2)
 CC kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
 CC complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
 CC siNAs have anorectic, antidiabetic, antiarteriosclerotic, cyostatic and
 CC virucide activities. The siNAs can be used to modulate expression of SCD
 CC genes, in cells, tissue explants or organisms, e.g. for treating obesity;
 CC diabetes (types I and II); arteriosclerosis; cancer and viral infections.
 CC They can also be used for drug screening; diagnosis; target
 CC identification and validation; genetic engineering; pharmacogenomics;
 CC studying gene function and gene mapping (e.g. of single-nucleotide
 CC polymorphisms). The present sequence represents an SCD siNA, which is
 CC used in the exemplification of the present invention.
 XX
 SQ Sequence 21 BP; 7 A; 2 C; 7 G; 2 T; 3 U; 0 Other;
 *
 Query Match 30.3%; Score 20; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. NO. 6.6;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3026 ACTGAACCACTGCTTCTT 3045
 DB 20 ACTGAACCACTGCTTCTT 1
 RESULT 11
 ADE27675/c
 ID ADE27675 standard; RNA; 21 BP.
 XX
 AC ADE27675;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Stearyl-CoA desaturase siNA oligonucleotide SEQ ID NO:630.
 XX
 KW short interfering nucleic acid; siNA; downregulation; inhibition; SCD;
 KW stearyl-CoA desaturase; RNA interference; anorectic; antidiabetic;
 KW antiarteriosclerotic; cyostatic; virucide; obesity; diabetes;
 KW arteriosclerosis; cancer; viral infection; drug screening;
 KW genetic engineering; pharmacogenomic; gene mapping; ss.
 XX
 OS Synthetic.
 XX
 PN WO2003070885-A2.
 XX
 PD 28-AUG-2003.
 XX
 PP 13-FEB-2003; 2003WO-US004317.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 06-JUN-2002; 2002US-036782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 20-SEP-2002; 2002US-0412304P.
 PR 15-JAN-2003; 2003US-0440129P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.

XX
 PI Mcswiggen J, Beigelman L, Thompson J;
 XX
 DR WPI; 2003-721687/68.
 XX
 PT New short interfering nucleic acid, useful e.g. for treatment and
 PT diagnosis of obesity or diabetes, downregulates expression of the
 PT stearyl-CoA desaturase gene.
 XX
 PS Disclosure; SEQ ID NO 630; 139pp; English.
 XX
 CC The present invention describes a short interfering nucleic acid (siNA)
 CC that downregulates expression of the SCD (stearyl-CoA desaturase) gene
 CC by RNA interference. Also described: (1) modulating expression of SCD
 CC genes in cells, tissue explants or organisms by introduction of siNA; (2)
 CC kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
 CC complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
 CC siNAs have anorectic, antidiabetic, antiarteriosclerotic, cyostatic and
 CC virucide activities. The siNAs can be used to modulate expression of SCD
 CC genes, in cells, tissue explants or organisms, e.g. for treating obesity;
 CC diabetes (types I and II); arteriosclerosis; cancer and viral infections.
 CC They can also be used for drug screening; diagnosis; target
 CC identification and validation; genetic engineering; pharmacogenomics;
 CC studying gene function and gene mapping (e.g. of single-nucleotide
 CC polymorphisms). The present sequence represents an SCD siNA, which is
 CC used in the exemplification of the present invention.
 XX
 SQ Sequence 21 BP; 7 A; 2 C; 7 G; 2 T; 3 U; 0 Other;
 *
 Query Match 30.3%; Score 20; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. NO. 6.6;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3026 ACTGAACCACTGCTTCTT 3045
 DB 20 ACTGAACCACTGCTTCTT 1
 RESULT 12
 ADO14557/c
 ID ADO14557 standard; RNA; 21 BP.
 XX
 AC ADO14557;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human interleukin-2-targeted siNA antisense strandSEQ ID NO:303.
 XX
 KW cyostatic; vasotropic; nephrotropic; cancer; reestenosis;
 KW polycystic kidney disease; RNA interference;
 KW short interfering nucleic acid; siNA; short interfering RNA; siRNA;
 KW double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
 KW expression modulation; gene therapy; drug screening; diagnosis;
 KW therapeutic target identification; pharmacogenomics;
 KW gene function analysis; gene mapping; human; interleukin-2; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key
 FH modified_base
 FT 1..8 Location/Qualifiers
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methyl base"
 FT modified_base
 FT 9
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-deoxy-2'-fluoro base"
 FT modified_base
 FT 10..11
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methyl base"
 FT modified_base
 FT 12
 FT /*tag= d

	/mod_base= OTHER
FT	/note= "2'-deoxy-2'-fluoro base"
PT	13 .14
FT	/*tag= e
TT	/mod_base= OTHER
FT	/note= "2'-O-methyl base"
modified_base	15 .17
FT	/*tag= f
FT	/mod_base= OTHER
FT	/note= "2'-deoxy-2'-fluoro base"
modified_base	18 .19
FT	/*tag= g
FT	/mod_base= OTHER
FT	/note= "2'-O-methyl base"
modified_base	20 .21
FT	/*tag= h
FT	/mod_base= OTHER
FT	/note= "Deoxyribonucleotide. Also, the internucleoside linkage is phosphorothioate or phosphorodithioate.
FT	Optionally linked to glyceryl moiety"
XX	
PN	WO2003070744-A1.
PD	
XD	28-Aug-2003.
XX	
PE	11-FEB-2003; 2003WO-US004566.
PR	20-FEB-2002; 2002US-0358580P.
PR	11-MAR-2002; 2002US-0363124P.
PR	06-JUN-2002; 2002US-0386783P.
PR	29-AUG-2002; 2002US-0406784P.
PR	05-SEP-2002; 2002US-0408378P.
PR	09-SEP-2002; 2002US-0409293P.
PR	15-JAN-2003; 2003US-0440123P.
XX	(RIBO-) RIBOZYME PHARM INC.
PA	
P1	Mcwiggen J, Beigelman L, Thompson J;
WI	MPJ, 2003-731546/69.
DR	
PT	New short interfering nucleic acid, useful e.g. for treatment and diagnosis of cancer, downregulates expression of an interleukin gene.
PS	Disclosure; SEQ ID NO 303; 138pp; English.
CC	The invention relates to short interfering nucleic acids (siRNA) which downregulate expression of the human interleukin-2 gene by RNA interference. The siRNAs may or may not comprise ribonucleotides and may be double or single stranded. They further comprise sense and antisense regions, or alternatively are assembled from a sense oligonucleotide and an antisense oligonucleotide. Specifically, the siRNAs include short interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siRNAs can be unmodified or chemically modified, expressed from a vector or enzymatically synthesised. The invention also expresses constructs for the delivery of siRNA. The siRNAs are used for treating cancer, restenosis and polycystic kidney disease. The siRNAs are also useful for drug screening, diagnostic, therapeutic target identification and validation, genetic engineering, pharmacogenomics, studying gene function, and gene mapping (e.g., of single nucleotide polymorphisms). The present sequence represents a the antisense strand of an exemplary chemically modified human interleukin-2-targeted double-stranded siNA.
Sequence	21 BP; 7 A; 2 C; 7 G; 2 T; 3 U; 0 Other;
Query Match	30.3%; Score 20; DB 1; Length 21;
Best Local Similarity	100.0%; Pred. No. 6.6;

Matches	20; Conservative	0; Mismatches	0; Indels	0; Gaps
QY	3026 ACTGACCACTGCTTCTCTT 3045			
Db	20 ACTGACCACTGCTTCTCTT 1			
RESULT 13				
AD014559/c				
ID	AD014559 standard; RNA; 21 BP.			
XX	AD014559;			
AC				
XX				
DT	01-JUL-2004 (first entry)			
XX				
DE	Human interleukin-2-targeted siNA antisense strandSEQ ID NO:305.			
XX				
KW	cytostatic; vasotropic; nephrotoxic; cancer; restenosis;			
KW	polycystic kidney disease; RNA interference;			
KW	short interfering nucleic acid; siNA; short interfering RNA; siRNA;			
KW	double-stranded RNA; micro-RNA; mRNA; short hairpin RNA; shRNA;			
KW	expression modulation; gene therapy; drug screening; diagnosis;			
KW	therapeutic target identification; pharmacogenomics;			
KW	gene function analysis; gene mapping; human; interleukin-2; ss.			
XX				
OS	Homo sapiens.			
XX				
PH	Key			
FT	modified_base			
FT	1. .8			
FT	/*tag= a			
FT	/mod_base= OTHER			
FT	/note= "2'-O-methyl base"			
FT	9			
FT	/*tag= b			
FT	/mod_base= OTHER			
FT	/note= "2'-deoxy-2'-fluoro base"			
FT	10. .11			
FT	/*tag= c			
FT	/mod_base= OTHER			
FT	/note= "2'-O-methyl base"			
FT	12			
FT	/*tag= d			
FT	/mod_base= OTHER			
FT	/note= "2'-deoxy-2'-fluoro base"			
FT	13. .14			
FT	/*tag= e			
FT	/mod_base= OTHER			
FT	/note= "2'-O-methyl base"			
FT	15. .17			
FT	/*tag= f			
FT	/mod_base= OTHER			
FT	/note= "2'-deoxy-2'-fluoro base"			
FT	18. .19			
FT	/*tag= g			
FT	/mod_base= OTHER			
FT	/note= "2'-O-methyl base"			
FT	20. .21			
FT	/*tag= h			
FT	/mod_base= OTHER			
FT	/note= "Deoxyribochimidine. Optionally linked to glyceryl moiety"			
FT				
XX				
PN	WO2003070744-A1.			
XX				
PD	28-AUG-2003.			
XX				
PR	11-FEB-2003; 2003WO-US004566.			
XX				
PR	20-FEB-2002; 2002US-0358580P.			
PR	11-MAR-2002; 2002US-0363124P.			
PR	06-JUN-2002; 2002US-0386782P.			
PR	29-AUG-2002; 2002US-0406784P.			
PR	05-SEP-2002; 2002US-0409378P.			

PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcsw1ggen J, Beigelman L, Thompson J;
XX WPI; 2003-731546/69.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of an interleukin gene.
XX
PS Disclosure; SEQ ID NO 305; 138bp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human interleukin-2 gene by RNA
CC interference. The siNA may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNA include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNA can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised,
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siRNA; conjugates
CC and/or complexes of siRNA; and vectors that express siRNA. The siNA are
CC used to modulate expression of the interleukin-2 gene in cells, tissue
CC explants or organisms (e.g., by ex vivo gene therapy), or in grafts and
CC transplants for the treatment of a variety of conditions. They may be
CC used for treating cancer, restenosis and polycystic kidney disease. The
CC siNA are also useful for drug screening, diagnosis, therapeutic target
CC identification and validation, genetic engineering, pharmacogenomics,
CC studying gene function, and gene mapping (e.g., of single nucleotide
CC polymorphisms). The present sequence represents a single antisense strand of
CC an exemplary chemically modified human interleukin-2-targeted double-
CC stranded siNA.
XX
SQ Sequence 21 BP; 7 A; 2 C; 7 G; 2 T; 3 U; 0 Other;
XX
Query Match 30.3%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 6.6;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 3026 ACTGAACACGCTCTCTCTT 3045
DB 20 ACTGAACACGCTCTCTCTT 1
XX
RESULT 14
AD014560/C
ID AD014560 standard; RNA; 21 BP.
XX
AC AD014560;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human interleukin-2-targeted siNA antisense strandSEQ ID NO:306.
XX
XX cytosinatic; vasotropic; nephrotropic; cancer; restenosis;
XX polycystic kidney disease; RNA interference;
XX short interfering nucleic acid; siNA; short interfering RNA; siRNA;
XX double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
XX expression modulation; gene therapy; drug screening; diagnosis;
XX therapeutic target identification; pharmacogenomics;
XX gene function analysis; gene mapping; human; interleukin-2; ss.
XX
XX Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..8
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Deoxy base"

FT modified_base 9
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-deoxy-2'-fluoro base"
FT 10..11
FT modified_base
FT /*tag= c
FT /mod_base= OTHER
FT /note= "Deoxy base"
FT 12
FT modified_base
FT /*tag= d
FT /mod_base= OTHER
FT /note= "2'-deoxy-2'-fluoro base"
FT 13..14
FT modified_base
FT /*tag= e
FT /mod_base= OTHER
FT /note= "Deoxy base"
FT 15..17
FT modified_base
FT /*tag= f
FT /mod_base= OTHER
FT /note= "2'-deoxy-2'-fluoro base"
FT 18..19
FT modified_base
FT /*tag= g
FT /mod_base= OTHER
FT /note= "Deoxy base"
FT 20..21
FT modified_base
FT /*tag= h
FT /mod_base= OTHER
FT /note= "Deoxyribohydride. Also, the internucleotide
FT linkage is phosphorothioate or phosphorodithioate.
FT Optionally linked to glyceryl moiety"
XX
PD W02003070744-A1.
XX
XX 28-AUG-2003.
XX
XX 11-FEB-2003; 2003WO-US004566.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 06-UTN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcsw1ggen J, Beigelman L, Thompson J;
XX WPI; 2003-731546/69.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
XX diagnosis of cancer, downregulates expression of an interleukin gene.
XX
XX Disclosure; SEQ ID NO 306; 138bp; English.
XX
XX The invention relates to short interfering nucleic acids (siNA) which
XX downregulate expression of the human interleukin-2 gene by RNA
XX interference. The siNA may or may not comprise ribonucleotides and may
XX be double or single stranded. They further comprise sense and antisense
XX regions, or alternatively are assembled from a sense oligonucleotide and
XX an antisense oligonucleotide. Specifically, the siNA include short
XX interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
XX hairpin RNA (shRNA). The siNA can be unmodified or chemically modified,
XX can contain deoxyribonucleotides, and can be chemically synthesised,
XX expressed from a vector or enzymatically synthesised. The invention also
XX relates to kits for the in vitro or in vivo delivery of siRNA; conjugates
XX and/or complexes of siRNA; and vectors that express siNA. The siNA are
XX used to modulate expression of the interleukin-2 gene in cells, tissue
XX explants or organisms (e.g., by ex vivo gene therapy), or in grafts and
XX transplants for the treatment of a variety of conditions. They may be
XX used for treating cancer, restenosis and polycystic kidney disease. The
XX siNA are also useful for drug screening, diagnosis, therapeutic target

XX (RIBO-) RIBOZYME PHARM INC.
XX Mcawiggen J, Beigelman L, Thompson J;
XX WPI; 2003-721687/68.
DR
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of obesity or diabetes, downregulates expression of the
PT stearyl-CoA desaturase gene.
XX
XX Example 3; SEQ ID NO 458; 139pp; English.
PS
XX The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of the SCD (stearyl-CoA desaturase) gene
CC by RNA interference. Also described: (1) modulating expression of SCD
CC genes in cells, tissue explants or organisms by introduction of siNA; (2)
CC kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
CC complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
CC siNAs have anorectic, antidiabetic, antiarteriosclerotic, cytostatic and
CC vinucide activities. The siNAs can be used to modulate expression of SCD
CC genes, in cells, tissue explants or organisms, e.g. for treating obesity;
CC diabetes (types I and II); arteriosclerosis; cancer and viral infections.
CC They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents an SCD siNA, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 19 BP; 3 A; 5 C; 5 G; 0 T; 6 U; 0 Other;
Query Match 28.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 8.9;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 3009 ACAGATGCTCAGGCTCAC 3027
Db 19 ACAGATGCTCAGGCTCAC 1
RESULT 19
ADE27225
ID ADE27225 standard; RNA; 19 BP.
XX
AC ADE27225;
XX
DT 29-JAN-2004 (first entry)
XX
DE Stearyl-CoA desaturase siNA oligonucleotide SEQ ID NO:169.
XX
XX short interfering nucleic acid; siNA; downregulation; inhibition; SCD;
KW stearyl-CoA desaturase; RNA interference; anorectic; antidiabetic;
KW antiarteriosclerotic; cytostatic; vinucide; obesity; diabetes;
KW arteriosclerosis; cancer; viral infection; drug screening;
KW genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
PN WO2003070885-A2.
XX
PD 28-AUG-2003.
XX
PF 13-FEB-2003; 2003WO-US004317.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 20-SEP-2002; 2002US-0412304P.
PR 15-JAN-2003; 2003US-0440129P.
XX

PA (RIBO-) RIBOZYME PHARM INC.
PI Mcawiggen J, Beigelman L, Thompson J;
XX WPI; 2003-721687/68.
DR
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of obesity or diabetes, downregulates expression of the
PT stearyl-CoA desaturase gene.
XX
XX Example 3; SEQ ID NO 169; 139pp; English.
PS
XX The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of the SCD (stearyl-CoA desaturase) gene
CC by RNA interference. Also described: (1) modulating expression of SCD
CC genes in cells, tissue explants or organisms by introduction of siNA; (2)
CC kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
CC complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
CC siNAs have anorectic, antidiabetic, antiarteriosclerotic, cytostatic and
CC vinucide activities. The siNAs can be used to modulate expression of SCD
CC genes, in cells, tissue explants or organisms, e.g. for treating obesity;
CC diabetes (types I and II); arteriosclerosis; cancer and viral infections.
CC They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents an SCD siNA, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 19 BP; 3 A; 7 C; 2 G; 0 T; 7 U; 0 Other;
Query Match 28.8%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 8.9;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
Qy 3027 CTGAACCACTGCTTCTCTT 3045
Db 1 CTGAACCACTGCTTCTCTT 19
RESULT 20
ADE27223
ID ADE27223 standard; RNA; 19 BP.
XX
AC ADE27223;
XX
DT 29-JAN-2004 (first entry)
XX
DE Stearyl-CoA desaturase siNA oligonucleotide SEQ ID NO:167.
XX
XX short interfering nucleic acid; siNA; downregulation; inhibition; SCD;
KW stearyl-CoA desaturase; RNA interference; anorectic; antidiabetic;
KW antiarteriosclerotic; cytostatic; vinucide; obesity; diabetes;
KW arteriosclerosis; cancer; viral infection; drug screening;
KW genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
PN WO2003070885-A2.
XX
PD 28-AUG-2003.
XX
PF 13-FEB-2003; 2003WO-US004317.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 20-SEP-2002; 2002US-0412304P.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.

XX Mcswiggen J, Beigelman L, Thompson J;
XX WPI; 2003-721687/68.
DR

PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of obesity or diabetes, downregulates expression of the
PT stearyl-CoA desaturase gene.
XX

PS Example 3; SEQ ID NO 167; 139pp; English.
XX

CC The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of the SCD (stearyl-CoA desaturase) gene
CC by RNA interference. Also described: (1) modulating expression of SCD
CC genes in cells, tissue explants or organisms by introduction of SCD
CC kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
CC complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
CC siNAs have anorectic, antidiabetic, antihypercholesteric, cytostatic and
CC virocidic activities. The siNAs can be used to modulate expression of SCD
CC genes, in cells, tissue explants or organisms, e.g. for treating obesity;
CC diabetes (types I and II); atherosclerosis; cancer and viral infections.
CC They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents an SCD siNA, which is
CC used in the exemplification of the present invention.
XX

SQ Sequence 19 BP; 3 A; 9 C; 4 G; 0 T; 3 U; 0 Other;
XX

Query Match 28.8%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.9;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2991 GGCAGCTCCCTCTCTGCACA 3009
Db 1 GGCAGCTCCCTCTCTGCACA 19

RESULT 21

ADE27513/C
ID ADE27513 standard; RNA; 19 BP.

AC ADE27513;

DT 29-JAN-2004 (first entry)

DE Stearyl-CoA desaturase siNA oligonucleotide SEQ ID NO:457.

XX short interfering nucleic acid; siNA; downregulation; inhibition; SCD;
XX stearyl-CoA desaturase; RNA interference; anorectic; antidiabetic;
XX antihypercholesteric; cytostatic; virocidic; obesity; diabetes;
XX atherosclerosis; cancer; viral infection; drug screening;
XX genetic engineering; pharmacogenomic; gene mapping; ss.
XX

OS Synthetic.

PN WO2003070885-A2.

PD 28-AUG-2003.

PF 13-FEB-2003; 2003WO-US004317.

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 06-JUN-2002; 2002US-036782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 20-SEP-2002; 2002US-0412304P.

PR 15-JAN-2003; 2003US-0440129P.

(RIBO-) RIBOZYME PHARM INC.

PI Mcswiggen J, Beigelman L, Thompson J;
XX WPI; 2003-721687/68.
DR

PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of obesity or diabetes, downregulates expression of the
PT stearyl-CoA desaturase gene.
XX

PS Example 3; SEQ ID NO 457; 139pp; English.
XX

CC The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of the SCD (stearyl-CoA desaturase) gene
CC by RNA interference. Also described: (1) modulating expression of SCD
CC genes in cells, tissue explants or organisms by introduction of SCD
CC kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
CC complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
CC siNAs have anorectic, antidiabetic, antihypercholesteric, cytostatic and
CC virocidic activities. The siNAs can be used to modulate expression of SCD
CC genes, in cells, tissue explants or organisms, e.g. for treating obesity;
CC diabetes (types I and II); atherosclerosis; cancer and viral infections.
CC They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents an SCD siNA, which is
CC used in the exemplification of the present invention.
XX

SQ Sequence 19 BP; 3 A; 4 C; 9 G; 0 T; 3 U; 0 Other;
XX

Query Match 28.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 8.9;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2991 GGCAGCTCCCTCTCTGCACA 3009
Db 19 GGCAGCTCCCTCTCTGCACA 1

RESULT 22

ADE27224
ID ADE27224 standard; RNA; 19 BP.

AC ADE27224;

DT 29-JAN-2004 (first entry)

DE Stearyl-CoA desaturase siNA oligonucleotide SEQ ID NO:168.

XX short interfering nucleic acid; siNA; downregulation; inhibition; SCD;
XX stearyl-CoA desaturase; RNA interference; anorectic; antidiabetic;
XX antihypercholesteric; cytostatic; virocidic; obesity; diabetes;
XX atherosclerosis; cancer; viral infection; drug screening;
XX genetic engineering; pharmacogenomic; gene mapping; ss.
XX

OS Synthetic.

PN WO2003070885-A2.

PD 28-AUG-2003.

PF 13-FEB-2003; 2003WO-US004317.

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 06-JUN-2002; 2002US-036782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 20-SEP-2002; 2002US-0412304P.

PR 15-JAN-2003; 2003US-0440129P.

(RIBO-) RIBOZYME PHARM INC.

Mcswiggen J, Beigelman L, Thompson J;


```
XX
DR WPI; 2003-721687/68.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of obesity or diabetes, downregulates expression of the
PT stearyl-CoA desaturase gene.
XX
PS Example 3; SEQ ID NO 168; 139pp; English.
XX
CC The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of the SCD (stearyl-CoA desaturase) gene
CC by RNA interference. Also described: (1) modulating expression of SCD
CC genes in cells, tissue explants or organisms by introduction of siNA; (2)
CC kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
CC complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
CC siNAs have anorectic, antidiabetic, antiarteriosclerotic, cytostatic and
CC virucide activities. The siNAs can be used to modulate expression of SCD
CC genes, in cells, tissue explants or organisms, e.g. for treating obesity;
CC diabetes (types I and II); arteriosclerosis; cancer and viral infections.
CC They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents an SCD siNA, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 19 BP; 6 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 28.8%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.9;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 3009 ACAGATGCTCAGGCTCAG 3027
Db 1 ACAGATGCTCAGGCTCAG 19
RESULT 23
ADE27515/c
ID ADE27515 standard; RNA; 19 BP.
XX
AC ADE27515;
DT 29-JAN-2004 (first entry)
XX
DE Stearyl-CoA desaturase siNA oligonucleotide SEQ ID NO:459.
XX
KW short interfering nucleic acid; siNA; downregulation; inhibition; SCD;
KW stearyl-CoA desaturase; RNA interference; anorectic; antidiabetic;
KW antiarteriosclerotic; cytostatic; virucide; obesity; diabetes;
KW arteriosclerosis; cancer; viral infection; drug screening;
KW genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
EN WO2003070885-A2.
XX
PD 28-AUG-2003.
XX
PF 13-FEB-2003; 2003WO-US004317.
XX
PR 20-FEB-2002; 2002US-0356580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408376P.
PR 09-SEP-2002; 2002US-0409293P.
PR 20-SEP-2002; 2002US-0412304P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcawiggen J, Beigelman L, Thompson J,
XX
```

```
DR WPI; 2003-721687/68.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of obesity or diabetes, downregulates expression of the
PT stearyl-CoA desaturase gene.
XX
PS Example 3; SEQ ID NO 459; 139pp; English.
XX
CC The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of the SCD (stearyl-CoA desaturase) gene
CC by RNA interference. Also described: (1) modulating expression of SCD
CC genes in cells, tissue explants or organisms by introduction of siNA; (2)
CC kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
CC complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
CC siNAs have anorectic, antidiabetic, antiarteriosclerotic, cytostatic and
CC virucide activities. The siNAs can be used to modulate expression of SCD
CC genes, in cells, tissue explants or organisms, e.g. for treating obesity;
CC diabetes (types I and II); arteriosclerosis; cancer and viral infections.
CC They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents an SCD siNA, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 19 BP; 7 A; 2 C; 7 G; 0 T; 3 U; 0 Other;
Query Match 28.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 8.9;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3027 CTGAACCACTGCTTCTCTT 3045
Db 19 CTGAACCACTGCTTCTCTT 1
```

Search completed: March 27, 2006, 08:28:38
Job time : 0.001 secs

THIS PAGE BLANK (USPTO)